UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancers, has announced the granting of inducement restricted stock units (RSUs) to 19 new employees. These RSUs, convertible into up to 71,800 ordinary shares of UroGen, are designed to support the commercialization of Jelmyto® and the company's pipeline development. The RSUs will vest equally over three years, with one-third vesting annually, contingent on continued employment. Granted under UroGen's 2019 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), these RSUs serve as an inducement for new hires joining the company.
UroGen Pharma (Nasdaq: URGN), un'azienda biotech focalizzata sui tumori uroteliali e speciali, ha annunciato l'assegnazione di unità azionarie vincolate per indennità (RSU) a 19 nuovi dipendenti. Queste RSU, convertibili in un massimo di 71.800 azioni ordinarie di UroGen, sono progettate per supportare la commercializzazione di Jelmyto® e lo sviluppo della pipeline dell'azienda. Le RSU si sbloccheranno in modo uniforme nel corso di tre anni, con un terzo che si sbloccherà annualmente, a condizione di un proseguimento dell'impiego. Concessa nell'ambito del Piano di Indennità 2019 di UroGen e in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), queste RSU fungono da incentivo per i nuovi assunti che entrano a far parte dell'azienda.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en cánceres uroteliales y especiales, ha anunciado la concesión de unidades de acciones restringidas por indención (RSU) a 19 nuevos empleados. Estas RSU, convertibles en un máximo de 71.800 acciones ordinarias de UroGen, están diseñadas para apoyar la comercialización de Jelmyto® y el desarrollo del pipeline de la empresa. Las RSU se liberarán equitativamente en un periodo de tres años, con un tercio liberándose anualmente, condicionado a la continuidad del empleo. Concedidas bajo el Plan de Inducción 2019 de UroGen y en cumplimiento con la Regla de Cotización de Nasdaq 5635(c)(4), estas RSU sirven como un incentivo para los nuevos contratados que se unen a la empresa.
UroGen Pharma (Nasdaq: URGN)는 요로 상피 및 특수 암에 중점을 둔 생명공학 회사로, 19명의 신입 직원에게 유인된 제한 주식 단위(RSU)를 부여했다고 발표했습니다. 이 RSU는 UroGen의 71,800주 일반 주식으로 전환할 수 있으며, Jelmyto®의 상용화와 회사 파이프라인 개발을 지원하기 위해 설계되었습니다. RSU는 3년에 걸쳐 균등히 분배되며, 연간 1/3씩 배분되며 계속 고용되는 조건입니다. UroGen의 2019년 유인 계획에 따라 부여되며 Nasdaq 상장 규정 5635(c)(4)에 부합하는 이 RSU는 회사에 새로 입사한 직원들을 위한 유인책 역할을 합니다.
UroGen Pharma (Nasdaq: URGN), une société de biotechnologie axée sur les cancers urothéliaux et spécialisés, a annoncé l'octroi d'unités d'actions restreintes (RSU) à 19 nouveaux employés. Ces RSU, convertibles en jusqu'à 71 800 actions ordinaires d'UroGen, sont conçues pour soutenir la commercialisation de Jelmyto® et le développement de la pipeline de la société. Les RSU s'acquitteront également sur trois ans, avec un tiers acquitté annuellement, sous réserve d'un emploi continu. Accordées dans le cadre du Plan d'Inducement 2019 d'UroGen et conformément à la Règle de Cotation Nasdaq 5635(c)(4), ces RSU servent d'incitation pour les nouveaux recrutés rejoignant l'entreprise.
UroGen Pharma (Nasdaq: URGN), ein Biotechnologieunternehmen, das sich auf uroteliale und spezielle Krebserkrankungen konzentriert, hat die Gewährung von eingeschränkten Aktieneinheiten (RSUs) an 19 neue Mitarbeiter bekannt gegeben. Diese RSUs, die in bis zu 71.800 Stammaktien von UroGen wandelbar sind, sollen die Kommerzialisierung von Jelmyto® und die Entwicklung der Unternehmenspipeline unterstützen. Die RSUs werden gleichmäßig über drei Jahre fällig, wobei ein Drittel jährlich fällig wird, sofern das Arbeitsverhältnis fortgesetzt wird. Gewährt im Rahmen des UroGen Inducement Plans 2019 und in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4), dienen diese RSUs als Anreiz für neue Mitarbeiter, die ins Unternehmen eintreten.
- Expansion of workforce with 19 new employees to support commercialization and development efforts
- Potential issuance of up to 71,800 ordinary shares through RSUs, aligning employee interests with company growth
- Potential dilution of existing shareholders due to issuance of new shares through RSUs
Up to 71,800 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.
The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in
Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905237247/en/
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3583
Source: UroGen Pharma Ltd.
FAQ
How many new employees received inducement grants from UroGen Pharma (URGN)?
What is the vesting schedule for the RSUs granted by UroGen Pharma (URGN)?
How many ordinary shares of UroGen (URGN) are issuable upon vesting of the granted RSUs?
What is the purpose of UroGen Pharma's (URGN) inducement grants to new employees?
